905 - Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis after Treatment Interruption: Results from the Octave Clinical Trials
Julián Panés(Hospital Clínic de Barcelona), Chinyu Su(Pfizer (United States)), Jean‐Frédéric Colombel(Mount Sinai Hospital), Nervin Lawendy(Pfizer (United States)), Brian Bressler(University of British Columbia), Deborah Woodworth(Pfizer (United States)), Haiying Zhang(Second Affiliated Hospital of Harbin Medical University), Eric S. Maller(Pfizer (United States)), Gary Chan, Leonardo Salese(Johnson & Johnson (United States))
Cited by 6
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k